Continuous Glucose Monitoring for Type 1 Diabetes

This trial tests whether the Dexcom G7 Continuous Glucose Monitor (CGM) manages blood sugar levels more effectively than the usual finger-prick test for people with Type 1 Diabetes in the hospital. Researchers aim to determine if the CGM can maintain blood sugar within the target range and reduce episodes of low blood sugar. Participants will be divided into two groups: one using the CGM and the other using the standard finger-prick method. This trial suits those with Type 1 Diabetes who have struggled to control their blood sugar levels and are hospitalized for at least three days. As an unphased trial, it offers a unique opportunity to explore innovative diabetes management strategies.

The trial does not specify if you need to stop taking your current medications, but it does require that you are treated with insulin therapy. It might be best to discuss your specific medications with the trial coordinators.

Research has shown that the Dexcom G7 Continuous Glucose Monitor (CGM) is accurate and safe for people with diabetes. In one study, participants used the Dexcom G7 for over 10 days, and it provided reliable blood sugar readings without major issues. Another study focused on pregnant individuals with diabetes and confirmed the device's safety and accuracy throughout pregnancy.

Unlike the standard of care for managing type 1 diabetes, which often involves periodic point-of-care (POC) glucose testing and insulin adjustments, the Dexcom G7 Continuous Glucose Monitor (CGM) offers a real-time, dynamic approach. This wearable device provides continuous glucose readings, allowing for more precise insulin therapy based on detailed glucose trends rather than sporadic checks. Researchers are excited about the Dexcom G7 because it can potentially improve glucose control by identifying glycemic excursions and preventing severe hyperglycemia more effectively. This real-time monitoring could lead to better overall diabetes management and improved patient outcomes.

Studies have shown that the Dexcom G7 Continuous Glucose Monitoring (CGM) system can significantly aid people with Type 1 Diabetes in managing their blood sugar levels. Specifically, users of the Dexcom CGM spend more time with their blood sugar in the healthy range of 70-180 mg/dl. Research also indicates that these users experience fewer instances of both low and high blood sugar. One study found that users reduced their A1C levels, a measure of long-term blood sugar control, by an average of 1%. This trial will compare the Dexcom G7 CGM system with standard glucose monitoring. Evidence suggests that the Dexcom G7 effectively helps people with Type 1 Diabetes maintain better blood sugar control.¹³⁴⁶⁷